Several development projects at Intravacc are publicly funded by national and international agencies. Writing proposals aimed at acquiring funding for novel vaccine concepts is a core activity of the Translational Research Department of Intravacc. The following is a sample of awarded funding.
In January 2024, Intravacc was awarded a contract of 633K USD from CARB-X for the development of a preventive vaccine against Neisseria gonorrhoeae (NG).
This vaccine will be developed on Intravacc’s proprietary outer membrane vesicle (OMV) platform technology. Through the tailored gonococcal antigens on the surface of the meningococcal OMV, Intravacc anticipates a significant enhancement in the vaccine candidate’s efficacy against gonorrhea.
Avacc 12: OMV bases intra-muscular vaccine against gonorrhea
In October 2022, Intravacc secured a 14.6 million USD contract from the US National Institute of Allergy and Infectious Diseases (NIAID) to develop an intranasal gonorrhea vaccine. The vaccine uses proprietary technology with IL-12-containing microspheres from Therapyx, Inc. and has demonstrated effectiveness in animal models, prompting further development. The project aims to advance the vaccine to phase I readiness study to evaluate safety and efficacy. Gonorrhea, a common sexually transmitted disease, lacks an effective vaccine, and antibiotic resistance is rising.
Avacc 11: first-in-class intranasal vaccine against gonorrhea
In October 2022, Intravacc was awarded a contract of 4.9 million USD from CEPI for the development of an Outer Membrane Vesicle-based, broadly protective beta coronavirus vaccine that builds on the technology of Avacc 10, Intravacc’s SARS-CoV-2 vaccine. The project aims to establish pre-clinical proof of concept of this innovative vaccine candidate.
In September 2020, Intravacc was awarded a contract with base and options that may total 9.4 million USD from the US National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), for the development of a prophylactic vaccine against enterovirus D68 (EV D68). EV D68 is a respiratory virus that is associated with a form of childhood paralysis called acute flaccid myelitis (AFM). In this project, an inactivated EV D68 vaccine will be developed up to a phase I clinical study that is foreseen to start in 2025.
In July 2022, Intravacc and the German Center for Neurogenerative Diseases (DZNE) secured 2.5 million EUR in EU funding to advance the development of an experimental ALS vaccine. ALS is a progressive neurodegenerative disease with no current cure. The project, funded through the European Union’s Horizon Europe research and innovation programme under grant agreement No 101057649 in the context of the European Innovation Council (EIC), focuses on establishing pre-clinical efficacy of a vaccine prototype that targets toxic poly-GA molecules associated with the disease and caused by the C9orf72 gene mutation.
You can send us an email:
info@intravacc.nl
Reach out to Business Development:
BD@intravacc.nl
Or pick up the phone:
+31 30 792 03 00
You can also just fill out the contact form on the right.
We look forward to hearing from you!
